Key Drivers
- Solid Margins
- Rising Debt
- Rich Valuation
AIAI Summary
Smith+Nephew now looks more like a margin-defense story than a growth rerating play: solid free cash flow and improved trading margins support earnings, but until U.S. orthopaedics and new launches re-accelerate revenue beyond low-single-digit growth, the current valuation leaves limited upside and argues for a hold.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Solid Margins
- •Rising Debt
- •Rich Valuation
SNN remains fundamentally solid on profitability and cash generation, but rising leverage, heavy intangibles, and a rich valuation make the stock look less attractive.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Tight resistance
- •Support at risk
SNN remains in a cautious short-term downtrend, with a failed breakout and repeated stalls near $30.10-$30.50 leaving $29.70-$29.80 support at risk until it reclaims $30.50 and then $31.50.
Failed breakout to $32.15 quickly reversed, showing sellers still defend rallies
Sentiment & News
Key News Insights:
- •Mixed growth
- •Lowered guidance
- •U.S. weakness
Smith+Nephew's Q2 showed modest strength in Sports Medicine and ENT, but weaker U.S. orthopaedics and wound care pushed the company to cut its full-year growth outlook and keep sentiment cautious.
The softer outlook and uneven operating performance likely limit near-term upside, even as select growth areas and partnerships support the long-term outpatient strategy
Similar Companies in Healthcare
Other companies in the same sector with AI ratings